Haemonetics (HAE) 10-Q 4 Nov 14 2015 Q2 Quarterly report Financial data

DOCUMENT_AND_ENTITY_INFORMATIO

DOCUMENT AND ENTITY INFORMATION	6 Months Ended
	Sep. 27, 2014
Document And Entity Information [Abstract]	'
Entity Registrant Name	'HAEMONETICS CORP
Entity Central Index Key	'0000313143
Current Fiscal Year End Date	'--03-28
Entity Filer Category	'Large Accelerated Filer
Document Type	'10-Q
Document Period End Date	27-Sep-14
Document Fiscal Year Focus	'2015
Document Fiscal Period Focus	'Q2
Amendment Flag	'false
Entity Common Stock, Shares Outstanding	51,336,678

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Income Statement [Abstract]	'	'	'	'
Net revenues	$227,580	$235,755	$452,068	$455,297
Cost of goods sold	119,466	115,871	237,676	224,002
Gross profit	108,114	119,884	214,392	231,295
Operating expenses:	'	'	'	'
Research and development	10,938	14,946	26,319	26,155
Selling, general and administrative	84,769	81,508	177,331	188,318
Total operating expenses	95,707	96,454	203,650	214,473
Operating income	12,407	23,430	10,742	16,822
Interest and other expense, net	-2,645	-2,542	-5,188	-5,183
Income before provision for income taxes	9,762	20,888	5,554	11,639
Provision for income taxes	2,275	4,340	1,715	2,965
Net income	7,487	16,548	3,839	8,674
Net income per share - basic (in dollars per share)	$0.15	$0.32	$0.07	$0.17
Net income per share - diluted (in dollars per share)	$0.14	$0.32	$0.07	$0.17
Weighted average shares outstanding	'	'	'	'
Basic (in shares)	51,391	51,492	51,567	51,360
Diluted (in shares)	51,925	52,361	52,056	52,200
Comprehensive income	$6,990	$15,308	$2,495	$7,174

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 27, 2014	Mar. 29, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$129,971	$192,469
Accounts receivable, less allowance of $2,067 at September 27, 2014 and $1,676 at March 29, 2014	151,055	164,603
Inventories, net	209,418	197,661
Deferred tax asset, net	14,149	14,144
Prepaid expenses and other current assets	52,366	54,099
Total current assets	556,959	622,976
Net property, plant and equipment	311,999	271,437
Intangible assets, less accumulated amortization of $117,770 at September 27, 2014 and $101,694 at March 29, 2014	257,544	271,159
Goodwill	336,301	336,768
Deferred tax asset, long term	1,071	1,184
Other long-term assets	10,671	10,654
Total assets	1,474,545	1,514,178
Current liabilities:	'	'
Notes payable and current maturities of long-term debt	1,655	45,630
Accounts payable	44,173	53,562
Accrued payroll and related costs	55,840	54,913
Accrued income taxes	3,347	3,113
Other liabilities	60,041	59,710
Total current liabilities	165,056	216,928
Long-term debt, net of current maturities	428,253	392,057
Long-term deferred tax liability	26,911	29,664
Other long-term liabilities	33,607	37,641
Stockholders’ equity:	'	'
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,336,678 shares at September 27, 2014 and 52,041,189 shares at March 29, 2014	513	520
Additional paid-in capital	408,940	402,611
Retained earnings	411,199	433,347
Accumulated other comprehensive income	66	1,410
Total stockholders’ equity	820,718	837,888
Total liabilities and stockholders’ equity	$1,474,545	$1,514,178

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 27, 2014	Mar. 29, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowance	$2,067	$1,676
Intangible assets, amortization	$117,770	$101,694
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,336,678	52,041,189
Common stock, shares outstanding (in shares)	51,336,678	52,041,189

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Cash Flows from Operating Activities:	'	'
Net income	$3,839	$8,674
Non-cash items:	'	'
Depreciation and amortization	41,625	38,256
Amortization of financing costs	572	815
Stock compensation expense	6,938	6,416
Purchase of in-process R&D	0	-3,569
Loss on sale of property, plant and equipment	364	265
Unrealized loss from hedging activities	554	2,266
Contingent consideration expense	459	310
Asset write-down	474	1,675
Change in operating assets and liabilities:	'	'
Decrease in accounts receivable, net	10,145	8,689
Increase in inventories	-13,185	-19,338
Increase in prepaid income taxes	-2,028	-1,459
(Decrease)/Increase in other assets and other liabilities	-8,160	5,067
Tax benefit of exercise of stock options	854	1,338
Increase/(Decrease) in accounts payable and accrued expenses	2,529	-13,781
Net cash provided by operating activities	44,980	42,762
Cash Flows from Investing Activities:	'	'
Capital expenditures on property, plant and equipment	-70,872	-28,202
Proceeds from sale of property, plant and equipment	377	642
Acquisition of Hemerus	0	-23,124
Other acquisitions and investments	0	8,707
Net cash used in investing activities	-70,495	-59,391
Cash Flows from Financing Activities:	'	'
Payments on long-term real estate mortgage	-513	-472
Net increase in short-term loans	786	4,240
Repayment of term loan borrowings	-8,531	-20,000
Proceeds from employee stock purchase plan	2,530	2,666
Proceeds from exercise of stock options	4,042	8,117
Excess tax benefit on exercise of stock options	0	1,581
Share repurchases	-33,770	0
Net cash used in financing activities	-35,456	-3,868
Effect of exchange rates on cash and cash equivalents	-1,527	525
Net Decrease in Cash and Cash Equivalents	-62,498	-19,972
Cash and Cash Equivalents at Beginning of Period	192,469	179,120
Cash and Cash Equivalents at End of Period	129,971	159,148
Non-cash Investing and Financing Activities:	'	'
Transfers from inventory to fixed assets for placement of Haemonetics equipment	4,026	6,034
Supplemental Disclosures of Cash Flow Information:	'	'
Interest paid	4,180	4,722
Income taxes paid	$8,351	$3,666

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Sep. 27, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
BASIS OF PRESENTATION	'
	BASIS OF PRESENTATION
	Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the six months ended are not necessarily indicative of the results that may be expected for the full fiscal year ending March 28, 2015, or any other interim period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 29, 2014.
	We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. We had no significant subsequent events.
	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2015 and 2014 include 52 weeks with each quarter having 13 weeks.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Sep. 27, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	RECENT ACCOUNTING PRONOUNCEMENTS
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity” (“ASU 2014-08”). ASU 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in this ASU are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. Management does not believe that the adoption of ASU 2014-08 will have a material effect on our Financial Statements.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 will be effective for the Company retrospectively beginning April 2, 2017, with early adoption not permitted. The impact on our Financial Statements of adopting ASU 2014-09 is being assessed by management.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. ASU 2014-12 is effective in our first quarter of fiscal 2017 with early adoption permitted using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. Management does not believe that the adoption of ASU 2014-08 will have a material effect on our Financial Statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ("ASU 2014-15") ASU 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for all entities in the first annual period ending after December 15, 2016; however, early adoption is permitted. Management does not believe that the adoption of ASU 2014-15 will have a material effect on our Financial Statements.

EARNINGS_PER_SHARE_EPS

EARNINGS PER SHARE ("EPS")	6 Months Ended
	Sep. 27, 2014
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE (EPS)	'
	EARNINGS PER SHARE (“EPS”)
	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
		Three Months Ended
	(In thousands, except per share amounts)	September 27,		September 28,
		2014		2013
	Basic EPS
	Net income	$	7,487	$	16,548
	Weighted average shares	51,391		51,492
	Basic income per share	$	0.15	$	0.32
	Diluted EPS
	Net income	$	7,487	$	16,548
	Basic weighted average shares	51,391		51,492
	Net effect of common stock equivalents	534		869
	Diluted weighted average shares	51,925		52,361
	Diluted income per share	$	0.14	$	0.32
		Six Months Ended
	(In thousands, except per share amounts)	September 27,		September 28,
		2014		2013
	Basic EPS
	Net income	$	3,839	$	8,674
	Weighted average shares	51,567		51,360
	Basic income per share	$	0.07	$	0.17
	Diluted EPS
	Net income	$	3,839	$	8,674
	Basic weighted average shares	51,567		51,360
	Net effect of common stock equivalents	489		840
	Diluted weighted average shares	52,056		52,200
	Diluted income per share	$	0.07	$	0.17
	Weighted average shares outstanding, assuming dilution, excludes the impact of 1.6 million shares for the three and six months ended September 27, 2014, and a negligible number and 0.8 million shares for the three and six months ended September 28, 2013, respectively, because these securities were anti-dilutive during the noted periods.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Sep. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	STOCK-BASED COMPENSATION
	Stock-based compensation expense of $6.9 million and $6.4 million was recognized for the six months ended September 27, 2014 and September 28, 2013, respectively. The related income tax benefit recognized was $2.2 million and $2.1 million for the six months ended September 27, 2014 and September 28, 2013, respectively.
	The weighted average fair value for our options granted was $8.08 and $10.98 for the six months ended September 27, 2014 and September 28, 2013, respectively. The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:
		Six Months Ended
		September 27,		September 28,
		2014		2013
	Stock Options Black-Scholes assumptions (weighted average):
	Volatility	22.62	%	25.49	%
	Expected life (years)	4.9		5
	Risk-free interest rate	1.8	%	1.4	%
	Dividend yield	—	%	—	%
	As of September 27, 2014, there was $22.5 million of total unrecognized compensation cost related to non-vested equity based compensation, including stock options, restricted stock units and markets stock units. This cost is expected to be recognized over a weighted average period of 2.18 years.
	During the six months ended September 27, 2014 and September 28, 2013, there were 97,415 and 81,465 shares, respectively, purchased under the Employee Stock Purchase Plan at an average price of $25.85 and $32.73 per share, respectively.

PRODUCT_WARRANTIES

PRODUCT WARRANTIES	6 Months Ended
	Sep. 27, 2014
Product Warranties Disclosures [Abstract]	'
PRODUCT WARRANTIES	'
	PRODUCT WARRANTIES
	We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
		Six Months Ended
	(In thousands)	September 27,			September 28,
		2014			2013
	Warranty accrual as of the beginning of the period	$	590		$	673
	Warranty provision	577			775
	Warranty spending	(595		)	(723		)
	Warranty accrual as of the end of the period	$	572		$	725

INVENTORIES

INVENTORIES	6 Months Ended
	Sep. 27, 2014
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	INVENTORIES
	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.
	(In thousands)	September 27,		March 29,
		2014		2014
	Raw materials	$	75,480	$	72,508
	Work-in-process	6,789		7,383
	Finished goods	127,149		117,770
		$	209,418	$	197,661

DERIVATIVES_AND_FAIR_VALUE_MEA

DERIVATIVES AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Sep. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
DERIVATIVES AND FAIR VALUE MEASUREMENTS	'
	DERIVATIVES AND FAIR VALUE MEASUREMENTS
	We manufacture, market and sell our products globally. For the six months ended September 27, 2014, approximately 45.8% of our sales were generated outside the US, generally in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.
	Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the US Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Swiss Francs, British Pounds, Australian Dollars, Canadian Dollars and Mexican Pesos. This does not eliminate the impact of the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.
	Designated Foreign Currency Hedge Contracts
	All of our designated foreign currency hedge contracts as of September 27, 2014 and March 29, 2014 were cash flow hedges under ASC 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $145.2 million as of September 27, 2014 and $157.9 million as of March 29, 2014.
	During the six months ended September 27, 2014, we recognized net gains of $1.6 million in earnings on our cash flow hedges, compared to recognized net gains of $1.7 million during the six months ended September 28, 2013. For the six months ended September 27, 2014, a $4.4 million gain related to foreign exchange hedge contracts, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gain of $1.7 million, net of tax, for the six months ended September 28, 2013. At September 27, 2014, gains of $4.4 million, net of tax, may be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of September 27, 2014 mature within twelve months.
	Non-Designated Foreign Currency Contracts
	We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $63.0 million as of September 27, 2014 and $72.9 million as of March 29, 2014.
	Interest Rate Swaps
	On August 1, 2012, we entered into a credit agreement which provided for a $475.0 million term loan (“Credit Agreement”). Under the terms of this Credit Agreement, we may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, we have chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow us to borrow in multiple tranches. As of September 27, 2014, we had three tranches outstanding, each based on Adjusted LIBOR. On June 30, 2014, we modified our Credit Agreement by extending the maturity date to July 1, 2019. Extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. The interest rates and LIBOR spreads remained the same in the modified Credit Agreement.
	Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. We formally document our hedge relationships (including identifying the hedged instrument and hedged item) at hedge inception to ensure that our interest rate swaps qualify for hedge accounting. On a quarterly basis, we assess whether the interest rate swaps are highly effective in offsetting changes in the cash flow of the hedged item. We do not hold or issue interest rate swaps for trading purposes. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.
	On December 21, 2012, we entered into two interest rate swap agreements (the "Swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional amount of $250.0 million of debt. The Swaps mature on August 1, 2017. We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. For the six months ended September 27, 2014, a loss of $0.1 million, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges.
	Fair Value of Derivative Instruments
	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in our consolidated statements of income and comprehensive income for the six months ended September 27, 2014.
	Derivative Instruments		Amount of				Amount of Gain/(Loss) Reclassified				Location in		Amount of Gain/(Loss)				Location in
			Gain/(Loss)				from AOCI into				Consolidated Statements of		Excluded from				Consolidated Statements of
			Recognized				Earnings				Income and Comprehensive Income		Effectiveness				Income and Comprehensive Income
			in AOCI				(Effective Portion)						Testing *
			(Effective Portion)
	(In thousands)
	Designated foreign currency hedge contracts, net of tax		$	4,443			$	1,638			Net revenues, COGS, and SG&A		$	142			Interest and other expense, net
	Non-designated foreign currency hedge contracts		—				—						2,680				Interest and other expense, net
	Designated interest rate swaps, net of tax		$	(106	)		$	—			Interest and other expense, net		$	—
	*   We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
	We did not have fair value hedges or net investment hedges outstanding as of September 27, 2014 or March 29, 2014.
	As of September 27, 2014, the amount recognized as a deferred tax asset for designated foreign currency hedges was $0.4 million and the amount recognized as a deferred tax liability for interest rate swap hedges was $0.4 million.
	ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of September 27, 2014, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of September 27, 2014 by type of contract and whether it is a qualifying hedge under ASC 815.
	(In thousands)		Location in		September 27, 2014				March 29, 2014
			Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts		Other current assets		$	5,069			$	2,574
	Designated interest rate swaps		Other current assets		1,080				1,250
					$	6,149			$	3,824
	Derivative Liabilities:
	Designated foreign currency hedge contracts		Other current liabilities		$	1,054			$	1,255
					$	1,054			$	1,255
	Other Fair Value Measurements
	ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC 820, for the six months ended September 27, 2014, we applied the requirements under ASC 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.
	On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.
	ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
	•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
	•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
	•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
	Fair Value Measured on a Recurring Basis
	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 27, 2014.
	(In thousands)		Quoted Market				Significant				Significant				Total
			Prices for				Other				Unobservable
			Identical Assets				Observable				Inputs
			(Level 1)				Inputs				(Level 3)
							(Level 2)
	Assets
	Money market funds		$	90,349			$	—			$	—			$	90,349
	Designated foreign currency hedge contracts		—				5,069				—				5,069
	Designated interest rate swap		—				1,080				—				1,080
			$	90,349			$	6,149			$	—			$	96,498
	Liabilities
	Designated foreign currency hedge contracts		$	—			$	1,054			$	—			$	1,054
	Contingent consideration		—				—				8,105				8,105
			$	—			$	1,054			$	8,105			$	9,159
	Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow over a ten year period.
	Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal operational budgets.
The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the quarter ended September 27, 2014.
(In thousands)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration as of March 29, 2014		$	7,645
Contingent consideration interest expense		460
Ending balance		$	8,105
The interest expense recognized on the contingent consideration is reflected in the "interest and other expense, net" on the
Consolidated Statements of Income and Comprehensive Income.
Other Fair Value Disclosures
The Term Loan which is carried at amortized cost and accounts receivable and accounts payable approximate fair value.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Sep. 27, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	We conduct business globally, and as a result, report our results of operations in a number of foreign jurisdictions in addition to the United States.  Our reported income tax rate is lower than the US federal statutory rate in all reported periods primarily as a result of being subject to lower income tax rates in the foreign jurisdictions where we operate.
	The reported income tax rate for the six months ended September 27, 2014 was 30.9%, as compared to a reported income tax rate of 25.5% for the six months ended September 28, 2013. Our reported income tax rate is lower than the US federal statutory tax rate in both periods primarily as a result of being subject to lower income tax rates in the foreign jurisdictions where we operate. In addition, during the current period we recorded pre-tax losses in Scotland and Malaysia due to restructuring costs associated with our manufacturing transformation, and we did not record a corresponding tax benefit due to uncertainty around our ability to realize a tax benefit in both jurisdictions. Similarly in the prior period, we recorded pre-tax losses in Italy associated with restructuring costs, and we did not recognize a tax benefit due to the full valuation allowance maintained against our Italian deferred tax assets.

DEBT

DEBT	6 Months Ended
	Sep. 27, 2014
Debt Disclosure [Abstract]	'
DEBT	'
	DEBT
	In connection with the acquisition of the whole blood business, we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million Term Loan and a $50.0 million revolving loan (the “Revolving Credit Facility”), and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities had a term of five years and matured on August 1, 2017. Interest was based on the Adjusted LIBOR plus a range of 1.125% to 1.500% depending on achievement of leverage ratios and customary credit terms which included financial and negative covenants.
	On June 30, 2014, we modified our existing Credit Facilities by extending the maturity date to July 1, 2019, extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. In addition, the amended Credit Agreement provides for a $100.0 million revolving credit facility and establishes interest rates in the range of LIBOR plus 1.125% – 1.500%, depending on certain conditions. At June 30, 2014, $379.4 million was outstanding under the term loan and $50.0 million was outstanding on the Revolving Credit Facility, both with an interest rate of 1.5625%. No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of approximately $429.4 million as of September 27, 2014. We were in compliance with the leverage and interest coverage ratios specified in the credit agreement as well as all other bank covenants as of September 27, 2014.
	The modified maturity profile is as follows:
	Fiscal year (in thousands)	Term Loan
	2015	$	—
	2016	14,227
	2017	37,941
	2018	73,510
	2019 and beyond	303,728
		$	429,406

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 27, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	COMMITMENTS AND CONTINGENCIES
	We are presently engaged in various legal actions, and although ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations.
	Italian Employment Litigation
	We have received notices of claimed violations of employment related contracts from some employees of the facility in Ascoli-Piceno, Italy where we have ceased manufacturing operations. These include actions claiming (i) working conditions and minimum salaries should have been established by different national collective bargaining agreements than those used over prior years, (ii) certain solidarity agreements, which are arrangements between the company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) payment of the extra time used for changing into and out of the working clothes at the beginning and end of each shift.
	In addition, a union represented in the Ascoli plant has filed an action claiming that the company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings.
	As of September 27, 2014, the total amount of damages claimed by the plaintiffs in these matters is approximately $4.3 million; however, it is not possible at this point in the proceedings to accurately evaluate the likelihood or amount of any potential losses. We believe these claims are without merit, and intend to defend against them. As such, no amounts have been accrued related to these claims. We may receive other, similar claims in the future.

SEGMENT_INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Sep. 27, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	SEGMENT INFORMATION
	Segment Definition Criteria
	We manage a global business which designs, manufactures and markets blood management solutions.  Our solutions are marketed through operating units organized based primarily on geography: North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific and Japan.
	ASC 280, Segment Reporting, permits aggregation of segments which are economically similar as well as similar in all of the following areas: (i) the nature of the products and services, (ii) the nature of the production processes, (iii) the type or class of customer for their products and services, (iv) the methods used to distribute their products or provide their services, and (v) the nature of the regulatory environment. We determined each operating segment is similar based on the criteria of ASC 280 and accordingly aggregate our five operating segments into one reportable segment. This conclusion is consistent with how our chief operating decision-maker views the business. Our chief operating decision maker primarily uses consolidated results to make operating and strategic decisions.
	Enterprise-Wide Disclosures about Product and Services
	We have four global product families: plasma, blood center, hospital, and software solutions.
	Our products include whole blood disposables, equipment devices and the related disposables used with these devices. Disposables include part of plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals. Blood center consists of disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients as well as disposables for manual whole blood collection. Hospital consists of surgical disposables (principally the Cell Saver® autologous blood recovery system targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries), the OrthoPAT® orthopedic perioperative autotransfusion system designed to operate both during and after surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG® Thrombelastograph® hemostasis analyzer used to help assess a surgical patient’s hemostasis during and after surgery).
	Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.
	Revenues from External Customers:
		Three Months Ended
	(In thousands)	September 27,		September 28,
		2014		2013
	Disposable revenues
	Plasma disposables	$	80,355	$	75,734
	Blood center disposables
	Platelet	39,370		39,884
	Red cell	10,176		10,221
	Whole blood	33,738		47,283
		83,284		97,388
	Hospital disposables
	Surgical	15,661		16,351
	OrthoPAT	4,898		6,262
	Diagnostics	10,047		7,985
		30,606		30,598
	Total disposables revenue	194,245		203,720
	Software solutions	18,145		17,120
	Equipment & other	15,190		14,915
	Net revenues	$	227,580	$	235,755
		Six Months Ended
	(In thousands)	September 27,		September 28,
		2014		2013
	Disposable revenues
	Plasma disposables	$	159,582	$	141,070
	Blood center disposables
	Platelet	77,541		74,330
	Red cell	20,422		20,229
	Whole blood	71,688		98,537
		169,651		193,096
	Hospital disposables
	Surgical	31,281		32,441
	OrthoPAT	10,279		12,581
	Diagnostics	19,645		15,579
		61,205		60,601
	Total disposables revenue	390,438		394,767
	Software solutions	35,883		33,866
	Equipment & other	25,747		26,664
	Net revenues	$	452,068	$	455,297

RESTRUCTURING

RESTRUCTURING	6 Months Ended
	Sep. 27, 2014
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING	'
	RESTRUCTURING
	On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete. From these reviews we identify opportunities to improve efficiencies, enhance commercial capabilities, better align our resources and offer customers better comprehensive solutions. In order to realize these opportunities, we undertake restructuring and other initiatives to transform our business.
	On May 1, 2013, we announced that our Board of Directors approved a plan to pursue identified Value Creation and Capture ("VCC") opportunities. These include: (i) investment in product line extensions, next generation products and growth platforms; (ii) enhancement of commercial execution capabilities by implementing go-to-market and other strategies to enable global profitable revenue growth; and (iii) transformation of the manufacturing network to best support these commercial strategies while optimizing expense levels. Collectively, these are opportunities to position us for optimal growth and increased competitiveness.
	Our manufacturing network transformation plan, part of our larger VCC activities previously announced, includes (i) discontinuing manufacturing activities at our Braintree, Massachusetts, Ascoli-Piceno, Italy and Bothwell, Scotland facilities, (ii) creating a technology center of excellence for product development, (iii) expanding of our current facility in Tijuana, Mexico, (iv) engaging Sanmina Corporation as a contract manufacturer to produce certain medical equipment, and (v) building a new manufacturing facility in Malaysia closer to our customers in Asia.
	We estimate we will incur approximately $74.0 million of restructuring and restructuring related expense and spend approximately $58.0 million on these initiatives in fiscal 2015. We estimate we will spend an additional $10 to $15 million to complete these initiatives through fiscal 2017.
	The following summarizes the restructuring activity for the six months ended September 27, 2014 and September 28, 2013:
		Six Months Ended September 27, 2014
	(In thousands)		Restructuring Accrual Balance at March 29, 2014		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at September 27, 2014
	Severance and other employee costs		$	22,908	$	12,743	$	(12,680	)	$	—		$	22,971
	Other costs		728		9,354		(9,704		)	—			378
	Accelerated depreciation		—		740		—			(740		)	—
	Asset write-down		—		96		—			(96		)	—
	Total		$	23,636	$	22,933	$	(22,384	)	$	(836	)	$	23,349
		Six Months Ended September 28, 2013
	(in thousands)		Restructuring Accrual Balance at March 30, 2013		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at September 28, 2013
	Severance and other employee costs		$	3,089	$	22,841	$	(6,565	)	$	—		$	19,365
	Other costs		173		5,317		(5,065		)	—			425
	Accelerated depreciation		—		1,188					(1,188		)	—
	Asset write-down		—		915		—			(915		)	—
			$	3,262	$	30,261	$	(11,630	)	$	(2,103	)	$	19,790
	We deployed significant financial resources for these activities.  Many of the activities necessary to complete the VCC initiatives include severance and other costs which qualify as restructuring expenses under ASC 420, Exit or Disposal Cost Obligations.  We incurred $22.9 million in severance, asset write-offs and other restructuring charges during the six months ended September 27, 2014. In addition, we also incurred $15.4 million of costs that do not constitute restructuring under ASC 420, which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, product line transfer teams and related costs, infrastructure related costs, accelerated depreciation and asset disposals.
	The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our statements of income and comprehensive income for the periods presented. The majority of expenses recorded as Transformation Costs in the prior year relate to the integration of the whole blood acquisition. Transformation Costs in the current year are associated with our VCC initiatives.
	Transformation costs		Three Months Ended				Six Months Ended
	(in thousands)		September 27,		September 28,		September 27,			September 28,
			2014		2013		2014			2013
	Transformation and other costs		$	7,225	$	10,868	$	14,987		$	20,083
	Accelerated depreciation		168		442		418			1,285
	Asset disposal		—		760		—			760
	Total		$	7,393	$	12,070	$	15,405		$	22,128
	Restructuring costs		Three Months Ended				Six Months Ended
	(in thousands)		September 27,		September 28,		September 27,			September 28,
			2014		2013		2014			2013
	Severance and other employee costs		$	3,222	$	2,606	$	12,743		$	22,841
	Other costs		4,249		2,676		9,354			5,317
	Accelerated depreciation		481		934		740			1,188
	Asset disposal		—		586		96			915
	Total		$	7,952	$	6,802	$	22,933		$	30,261
	Total restructuring and transformation		$	15,345	$	18,872	$	38,338		$	52,389

CAPITALIZATION_OF_SOFTWARE_DEV

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	6 Months Ended
	Sep. 27, 2014
Research and Development [Abstract]	'
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	'
	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS
	For costs incurred related to the development of software to be sold, leased, or otherwise marketed, we apply the provisions of ASC 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers.
	We capitalized $3.5 million and $2.6 million in software development costs for ongoing initiatives during the six months ended September 27, 2014 and September 28, 2013, respectively. At September 27, 2014 and March 29, 2014, we have a total of $35.2 million and $31.7 million of software costs capitalized, of which $6.7 million and $15.6 million are related to in-process software development initiatives, respectively. During the second quarter of fiscal 2015, our next generation plasma software received 510(k) approval and $12.3 million of capitalized costs was placed into service. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. We review these assets for impairment at least annually.

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE INCOME	6 Months Ended
	Sep. 27, 2014
Stockholders' Equity Note [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE INCOME	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME
	The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the six months ended September 27, 2014:
	(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
	Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
	Other comprehensive income (loss) before reclassifications	(3,446		)	(597		)	4,337			294
	Amounts reclassified from Accumulated Other Comprehensive Income	—			—			(1,638		)	(1,638		)
	Net current period other comprehensive income	(3,446		)	(597		)	2,699			(1,344		)
	Balance as of September 27, 2014	$	(248	)	$	(5,189	)	$	5,503		$	66
	The details about the amount reclassified from Accumulated Other Comprehensive Income for the six months ended September 27, 2014 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income			Affected Line in the
					Statement of Income
	Derivative instruments reclassified to income statement
	Realized net gain on derivatives	$	1,676		Revenue, cost of goods sold, income/(expense)
	Income tax effect	(38		)	Provision for income taxes
	Net of taxes	$	1,638

EARNINGS_PER_SHARE_EPS_Tables

EARNINGS PER SHARE ("EPS") (Tables)	6 Months Ended
	Sep. 27, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share Reconciliation	'
	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
		Three Months Ended
	(In thousands, except per share amounts)	September 27,		September 28,
		2014		2013
	Basic EPS
	Net income	$	7,487	$	16,548
	Weighted average shares	51,391		51,492
	Basic income per share	$	0.15	$	0.32
	Diluted EPS
	Net income	$	7,487	$	16,548
	Basic weighted average shares	51,391		51,492
	Net effect of common stock equivalents	534		869
	Diluted weighted average shares	51,925		52,361
	Diluted income per share	$	0.14	$	0.32
		Six Months Ended
	(In thousands, except per share amounts)	September 27,		September 28,
		2014		2013
	Basic EPS
	Net income	$	3,839	$	8,674
	Weighted average shares	51,567		51,360
	Basic income per share	$	0.07	$	0.17
	Diluted EPS
	Net income	$	3,839	$	8,674
	Basic weighted average shares	51,567		51,360
	Net effect of common stock equivalents	489		840
	Diluted weighted average shares	52,056		52,200
	Diluted income per share	$	0.07	$	0.17

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Sep. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Assumptions Utilized for Estimating Fair Value of Option Grants	'
	The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:
		Six Months Ended
		September 27,		September 28,
		2014		2013
	Stock Options Black-Scholes assumptions (weighted average):
	Volatility	22.62	%	25.49	%
	Expected life (years)	4.9		5
	Risk-free interest rate	1.8	%	1.4	%
	Dividend yield	—	%	—	%

PRODUCT_WARRANTIES_Tables

PRODUCT WARRANTIES (Tables)	6 Months Ended
	Sep. 27, 2014
Product Warranties Disclosures [Abstract]	'
Schedule of Product Warranty Liability	'
	We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
		Six Months Ended
	(In thousands)	September 27,			September 28,
		2014			2013
	Warranty accrual as of the beginning of the period	$	590		$	673
	Warranty provision	577			775
	Warranty spending	(595		)	(723		)
	Warranty accrual as of the end of the period	$	572		$	725

INVENTORIES_Tables

INVENTORIES (Tables)	6 Months Ended
	Sep. 27, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.
	(In thousands)	September 27,		March 29,
		2014		2014
	Raw materials	$	75,480	$	72,508
	Work-in-process	6,789		7,383
	Finished goods	127,149		117,770
		$	209,418	$	197,661

DERIVATIVES_AND_FAIR_VALUE_MEA1

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Sep. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	'
	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in our consolidated statements of income and comprehensive income for the six months ended September 27, 2014.
	Derivative Instruments	Amount of				Amount of Gain/(Loss) Reclassified				Location in		Amount of Gain/(Loss)				Location in
		Gain/(Loss)				from AOCI into				Consolidated Statements of		Excluded from				Consolidated Statements of
		Recognized				Earnings				Income and Comprehensive Income		Effectiveness				Income and Comprehensive Income
		in AOCI				(Effective Portion)						Testing *
		(Effective Portion)
	(In thousands)
	Designated foreign currency hedge contracts, net of tax	$	4,443			$	1,638			Net revenues, COGS, and SG&A		$	142			Interest and other expense, net
	Non-designated foreign currency hedge contracts	—				—						2,680				Interest and other expense, net
	Designated interest rate swaps, net of tax	$	(106	)		$	—			Interest and other expense, net		$	—
	*   We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	'
	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of September 27, 2014 by type of contract and whether it is a qualifying hedge under ASC 815.
	(In thousands)	Location in		September 27, 2014				March 29, 2014
		Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts	Other current assets		$	5,069			$	2,574
	Designated interest rate swaps	Other current assets		1,080				1,250
				$	6,149			$	3,824
	Derivative Liabilities:
	Designated foreign currency hedge contracts	Other current liabilities		$	1,054			$	1,255
				$	1,054			$	1,255
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	'
	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 27, 2014.
	(In thousands)	Quoted Market				Significant				Significant				Total
		Prices for				Other				Unobservable
		Identical Assets				Observable				Inputs
		(Level 1)				Inputs				(Level 3)
						(Level 2)
	Assets
	Money market funds	$	90,349			$	—			$	—			$	90,349
	Designated foreign currency hedge contracts	—				5,069				—				5,069
	Designated interest rate swap	—				1,080				—				1,080
		$	90,349			$	6,149			$	—			$	96,498
	Liabilities
	Designated foreign currency hedge contracts	$	—			$	1,054			$	—			$	1,054
	Contingent consideration	—				—				8,105				8,105
		$	—			$	1,054			$	8,105			$	9,159
Schedule of Fair Value Measurements Using Significant Unobservable Inputs (Level 3)	'
	The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the quarter ended September 27, 2014.
	(In thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Contingent consideration as of March 29, 2014	$	7,645
	Contingent consideration interest expense	460
	Ending balance	$	8,105

DEBT_Tables

DEBT (Tables)	6 Months Ended
	Sep. 27, 2014
Debt Disclosure [Abstract]	'
Schedule of Maturities of Long-term Debt	'
	The modified maturity profile is as follows:
	Fiscal year (in thousands)	Term Loan
	2015	$	—
	2016	14,227
	2017	37,941
	2018	73,510
	2019 and beyond	303,728
		$	429,406

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	6 Months Ended
	Sep. 27, 2014
Segment Reporting [Abstract]	'
Schedule of Revenues from External Customers	'
	Revenues from External Customers:
		Three Months Ended
	(In thousands)	September 27,		September 28,
		2014		2013
	Disposable revenues
	Plasma disposables	$	80,355	$	75,734
	Blood center disposables
	Platelet	39,370		39,884
	Red cell	10,176		10,221
	Whole blood	33,738		47,283
		83,284		97,388
	Hospital disposables
	Surgical	15,661		16,351
	OrthoPAT	4,898		6,262
	Diagnostics	10,047		7,985
		30,606		30,598
	Total disposables revenue	194,245		203,720
	Software solutions	18,145		17,120
	Equipment & other	15,190		14,915
	Net revenues	$	227,580	$	235,755
		Six Months Ended
	(In thousands)	September 27,		September 28,
		2014		2013
	Disposable revenues
	Plasma disposables	$	159,582	$	141,070
	Blood center disposables
	Platelet	77,541		74,330
	Red cell	20,422		20,229
	Whole blood	71,688		98,537
		169,651		193,096
	Hospital disposables
	Surgical	31,281		32,441
	OrthoPAT	10,279		12,581
	Diagnostics	19,645		15,579
		61,205		60,601
	Total disposables revenue	390,438		394,767
	Software solutions	35,883		33,866
	Equipment & other	25,747		26,664
	Net revenues	$	452,068	$	455,297

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	6 Months Ended
	Sep. 27, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring Reserve by Type of Cost	'
	The following summarizes the restructuring activity for the six months ended September 27, 2014 and September 28, 2013:
		Six Months Ended September 27, 2014
	(In thousands)		Restructuring Accrual Balance at March 29, 2014		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at September 27, 2014
	Severance and other employee costs		$	22,908	$	12,743	$	(12,680	)	$	—		$	22,971
	Other costs		728		9,354		(9,704		)	—			378
	Accelerated depreciation		—		740		—			(740		)	—
	Asset write-down		—		96		—			(96		)	—
	Total		$	23,636	$	22,933	$	(22,384	)	$	(836	)	$	23,349
		Six Months Ended September 28, 2013
	(in thousands)		Restructuring Accrual Balance at March 30, 2013		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at September 28, 2013
	Severance and other employee costs		$	3,089	$	22,841	$	(6,565	)	$	—		$	19,365
	Other costs		173		5,317		(5,065		)	—			425
	Accelerated depreciation		—		1,188					(1,188		)	—
	Asset write-down		—		915		—			(915		)	—
			$	3,262	$	30,261	$	(11,630	)	$	(2,103	)	$	19,790
Schedule of Restructuring and Related Costs	'
	The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our statements of income and comprehensive income for the periods presented. The majority of expenses recorded as Transformation Costs in the prior year relate to the integration of the whole blood acquisition. Transformation Costs in the current year are associated with our VCC initiatives.
	Transformation costs		Three Months Ended				Six Months Ended
	(in thousands)		September 27,		September 28,		September 27,			September 28,
			2014		2013		2014			2013
	Transformation and other costs		$	7,225	$	10,868	$	14,987		$	20,083
	Accelerated depreciation		168		442		418			1,285
	Asset disposal		—		760		—			760
	Total		$	7,393	$	12,070	$	15,405		$	22,128
	Restructuring costs		Three Months Ended				Six Months Ended
	(in thousands)		September 27,		September 28,		September 27,			September 28,
			2014		2013		2014			2013
	Severance and other employee costs		$	3,222	$	2,606	$	12,743		$	22,841
	Other costs		4,249		2,676		9,354			5,317
	Accelerated depreciation		481		934		740			1,188
	Asset disposal		—		586		96			915
	Total		$	7,952	$	6,802	$	22,933		$	30,261
	Total restructuring and transformation		$	15,345	$	18,872	$	38,338		$	52,389

COMPREHENSIVE_INCOME_Tables

COMPREHENSIVE INCOME (Tables)	6 Months Ended
	Sep. 27, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The following is a roll-forward of the components of Accumulated Other Comprehensive Income, net of tax, for the six months ended September 27, 2014:
	(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
	Balance as of March 29, 2014	$	3,198		$	(4,592	)	$	2,804		$	1,410
	Other comprehensive income (loss) before reclassifications	(3,446		)	(597		)	4,337			294
	Amounts reclassified from Accumulated Other Comprehensive Income	—			—			(1,638		)	(1,638		)
	Net current period other comprehensive income	(3,446		)	(597		)	2,699			(1,344		)
	Balance as of September 27, 2014	$	(248	)	$	(5,189	)	$	5,503		$	66
Reclassification out of Accumulated Other Comprehensive Income	'
	The details about the amount reclassified from Accumulated Other Comprehensive Income for the six months ended September 27, 2014 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income			Affected Line in the
					Statement of Income
	Derivative instruments reclassified to income statement
	Realized net gain on derivatives	$	1,676		Revenue, cost of goods sold, income/(expense)
	Income tax effect	(38		)	Provision for income taxes
	Net of taxes	$	1,638

BASIS_OF_PRESENTATION_Narrativ

BASIS OF PRESENTATION (Narrative) (Details)	6 Months Ended	12 Months Ended
	Sep. 27, 2014	Mar. 29, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Term of each fiscal year	'364 days	'364 days
Term of each quarter	'91 days	'91 days

EARNINGS_PER_SHARE_EPS_Schedul

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Basic EPS	'	'	'	'
Net income	$7,487	$16,548	$3,839	$8,674
Basic weighted average shares (in shares)	51,391,000	51,492,000	51,567,000	51,360,000
Basic income per share (in dollars per share)	$0.15	$0.32	$0.07	$0.17
Diluted EPS	'	'	'	'
Net income	$7,487	$16,548	$3,839	$8,674
Basic weighted average shares (in shares)	51,391,000	51,492,000	51,567,000	51,360,000
Net effect of common stock equivalents (in shares)	534,000	869,000	489,000	840,000
Diluted weighted average shares (in shares)	51,925,000	52,361,000	52,056,000	52,200,000
Diluted income per share (in dollars per share)	$0.14	$0.32	$0.07	$0.17
Stock options excluded from computation of weighted average shares outstanding (in shares)	'	'	1,600,000	800,000

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Stock-based compensation expense recognized	'	'	$6.90	$6.40
Tax benefit from compensation expense	'	'	2.2	2.1
Weighted average fair value of options granted (in dollars per share)	'	'	$8.08	$10.98
Total unrecognized compensation cost related to non-vested stock options	$22.50	'	$22.50	'
Total unrecognized compensation cost related to non-vested stock options, weighted average period of recognition	'	'	'2 years 2 months 5 days	'
Stock Options Black-Scholes assumptions (weighted average):	'	'	'	'
Volatility	22.62%	25.49%	'	'
Expected life (years)	'4 years 10 months 24 days	'5 years	'	'
Risk-free interest rate	1.80%	1.40%	'	'
Dividend yield	0.00%	0.00%	'	'
Shares purchased under the ESPP (in shares)	'	'	97,415	81,465
Shares purchased under the ESPP (in dollars per share)	'	'	$25.85	$32.73

PRODUCT_WARRANTIES_Schedule_of

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Product Warranties [Roll Forward]	'	'
Warranty accrual as of the beginning of the period	$590	$673
Warranty provision	577	775
Warranty spending	-595	-723
Warranty accrual as of the end of the period	$572	$725

INVENTORIES_Schedule_of_Invent

INVENTORIES (Schedule of Inventories) (Details) (USD $)	Sep. 27, 2014	Mar. 29, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$75,480	$72,508
Work-in-process	6,789	7,383
Finished goods	127,149	117,770
Inventories, net	$209,418	$197,661

DERIVATIVES_AND_FAIR_VALUE_MEA2

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) (USD $)	6 Months Ended				3 Months Ended		6 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 27, 2014	Sep. 27, 2014	Sep. 27, 2014	Sep. 27, 2014	Sep. 27, 2014
	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Not Designated as Hedging Instrument	Not Designated as Hedging Instrument
	Cash Flow Hedging	Cash Flow Hedging	Cash Flow Hedging	Cash Flow Hedging	Cash Flow Hedging	Interest Rate Swap [Member]	Interest Rate Swap [Member]	Interest Rate Swap [Member]	Foreign Exchange Contract	Foreign Exchange Contract
	Foreign Exchange Contract	Foreign Exchange Contract	Foreign Exchange Contract	Foreign Exchange Contract	Foreign Exchange Contract			Interest and other expense, net		Interest and other expense, net
			Net revenues, COGS, and SG&A	Net revenues, COGS, and SG&A	Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'	'	'	'	'	'
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	($4,443)	($1,700)	'	'	'	'	$106	'	$0	'
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	'	'	1,638	1,700	'	'	'	0	0	'
Amount Excluded from Effectiveness Testing	'	'	'	'	$142	$0	'	'	'	$2,680

DERIVATIVES_AND_FAIR_VALUE_MEA3

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) (USD $)	Sep. 27, 2014	Mar. 29, 2014
In Thousands, unless otherwise specified
Derivative Assets:	'	'
Derivative Assets	$6,149	$3,824
Derivative Liabilities:	'	'
Derivative Liabilities	1,054	1,255
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Assets	'	'
Derivative Assets:	'	'
Derivative Assets	5,069	2,574
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Liabilities	'	'
Derivative Liabilities:	'	'
Derivative Liabilities	1,054	1,255
Designated as Hedging Instrument | Interest Rate Swap [Member] | Other Current Assets	'	'
Derivative Assets:	'	'
Derivative Assets	$1,080	$1,250

DERIVATIVES_AND_FAIR_VALUE_MEA4

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Mar. 29, 2014
Assets	'	'
Money market funds	$90,349	'
Designated foreign currency hedge contracts	5,069	'
Designated interest rate swap	1,080	'
Assets, Fair Value Disclosure, Total	96,498	'
Liabilities	'	'
Designated foreign currency hedge contracts	1,054	'
Contingent consideration	8,105	'
Liabilities, Fair Value Disclosure	9,159	'
Quoted Market Prices for Identical Assets (Level 1)	'	'
Assets	'	'
Money market funds	90,349	'
Designated foreign currency hedge contracts	0	'
Designated interest rate swap	0	'
Assets, Fair Value Disclosure, Total	90,349	'
Liabilities	'	'
Designated foreign currency hedge contracts	0	'
Contingent consideration	0	'
Liabilities, Fair Value Disclosure	0	'
Significant Other Observable Inputs (Level 2)	'	'
Assets	'	'
Money market funds	0	'
Designated foreign currency hedge contracts	5,069	'
Designated interest rate swap	1,080	'
Assets, Fair Value Disclosure, Total	6,149	'
Liabilities	'	'
Designated foreign currency hedge contracts	1,054	'
Contingent consideration	0	'
Liabilities, Fair Value Disclosure	1,054	'
Significant Unobservable Inputs (Level 3)	'	'
Assets	'	'
Money market funds	0	'
Designated foreign currency hedge contracts	0	'
Designated interest rate swap	0	'
Assets, Fair Value Disclosure, Total	0	'
Liabilities	'	'
Designated foreign currency hedge contracts	0	'
Contingent consideration	8,105	'
Liabilities, Fair Value Disclosure	8,105	'
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)	'	'
Contingent consideration as of March 29, 2014	'	7,645
Contingent consideration interest expense	460	'
Ending balance	$8,105	$7,645

DERIVATIVES_AND_FAIR_VALUE_MEA5

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) (USD $)

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

Sep. 27, 2014

Mar. 29, 2014

Aug. 03, 2012

Jun. 28, 2014

Aug. 01, 2012

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 28, 2013

Dec. 21, 2012

Sep. 27, 2014

Sep. 27, 2014

Sep. 28, 2013

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Designated as Hedging Instrument

Net revenues, COGS, and SG&A

Net revenues, COGS, and SG&A

Foreign Exchange Contract

Interest Rate Swap [Member]

Cash Flow Hedging

Cash Flow Hedging

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Designated as Hedging Instrument

Designated as Hedging Instrument

Foreign Exchange Contract

Foreign Exchange Contract

Cash Flow Hedging

Cash Flow Hedging

Foreign Exchange Contract

Foreign Exchange Contract

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of sales generated outside the US

45.80%

'

'

'

'

'

'

'

'

'

'

'

'

Maturity period for foreign currency contracts (in years)

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

Designated foreign currency hedge contracts outstanding

$145,200,000

$157,900,000

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in AOCI (Effective Portion)

'

'

'

'

'

'

'

4,443,000

1,700,000

'

-106,000

'

'

Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)

'

'

'

'

'

'

'

'

'

'

'

1,638,000

1,700,000

Gains reclassified to AOCI in next 12 months

-4,400,000

'

'

'

'

'

'

'

'

'

'

'

'

Non-designated foreign currency hedge contracts outstanding

63,000,000

72,900,000

'

'

'

'

'

'

'

'

'

'

'

Face amount of debt

'

'

'

475,000,000

475,000,000

'

'

'

'

'

'

'

'

Description of variable rate basis

'

'

'1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”)

'

'

'

'

'

'

'LIBOR

'

'

'

Derivative, fixed interest rate

'

'

'

'

'

'

'

'

'

0.68%

'

'

'

Deferred income tax expense (benefit)

'

'

'

'

'

400,000

400,000

'

'

'

'

'

'

Notional amount of derivative

'

'

'

'

'

'

'

'

'

$250,000,000

'

'

'

INCOME_TAXES_Details

INCOME TAXES (Details)	6 Months Ended
	Sep. 27, 2014	Sep. 28, 2013
Income Tax Disclosure [Abstract]	'	'
Reported tax rate	30.90%	25.50%

DEBT_Details

DEBT (Details) (USD $)

Sep. 27, 2014

Jun. 28, 2014

Sep. 27, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 28, 2014

Jun. 30, 2014

Jun. 28, 2014

Jun. 30, 2014

Jun. 28, 2014

Aug. 01, 2012

Jun. 30, 2014

Jun. 28, 2014

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

London Interbank Offered Rate (LIBOR) [Member]

London Interbank Offered Rate (LIBOR) [Member]

London Interbank Offered Rate (LIBOR) [Member]

London Interbank Offered Rate (LIBOR) [Member]

London Interbank Offered Rate (LIBOR) [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Face amount of debt

'

'

'

'

'

'

'

'

'

$475,000,000

$475,000,000

'

$50,000,000

Term of credit facilities

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Interest Rate

'

'

'

'

1.13%

1.13%

1.50%

1.50%

'

'

'

'

'

Debt outstanding

429,406,000

'

429,400,000

'

'

'

'

'

379,400,000

'

'

50,000,000

'

Effective interest rate

'

'

'

1.56%

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

2015

0

'

'

'

'

'

'

'

'

'

'

'

'

2016

14,227,000

'

'

'

'

'

'

'

'

'

'

'

'

2017

37,941,000

'

'

'

'

'

'

'

'

'

'

'

'

2018

73,510,000

'

'

'

'

'

'

'

'

'

'

'

'

2019 and beyond

$303,728,000

'

'

'

'

'

'

'

'

'

'

'

'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Sep. 27, 2014
In Millions, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
Damages claimed	$4.30

SEGMENT_INFORMATION_Revenues_f

SEGMENT INFORMATION (Revenues from External Customers) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
			segment
			product
Segment Reporting [Abstract]	'	'	'	'
Number of operating segments	'	'	5	'
Number of global product families	'	'	4	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	$227,580	$235,755	$452,068	$455,297
Plasma Disposables [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	80,355	75,734	159,582	141,070
Blood Center [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	83,284	97,388	169,651	193,096
Platelet [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	39,370	39,884	77,541	74,330
Red Cell [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	10,176	10,221	20,422	20,229
Whole Blood [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	33,738	47,283	71,688	98,537
Hospital [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	30,606	30,598	61,205	60,601
Surgical [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	15,661	16,351	31,281	32,441
OrthoPAT [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	4,898	6,262	10,279	12,581
Diagnostics [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	10,047	7,985	19,645	15,579
Disposables Revenue [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	194,245	203,720	390,438	394,767
Software Solutions [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	18,145	17,120	35,883	33,866
Equipment and Other [Member]	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Net revenues	$15,190	$14,915	$25,747	$26,664

RESTRUCTURING_Narrative_Detail

RESTRUCTURING (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Expected cost	$74,000,000	'	$74,000,000	'
Expected cost in cash	'	'	58,000,000	'
Restructuring Costs Incurred	7,952,000	6,802,000	22,933,000	30,261,000
Transformation costs	7,393,000	12,070,000	15,405,000	22,128,000
Minimum [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Expected cost	10,000,000	'	10,000,000	'
Maximum [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Expected cost	$15,000,000	'	$15,000,000	'

RESTRUCTURING_Schedule_of_Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Restructuring Reserve [Roll Forward]	'	'	'	'
Restructuring Accrual Balance	'	'	$23,636	$3,262
Restructuring Costs Incurred	7,952	6,802	22,933	30,261
Less Payments	'	'	-22,384	-11,630
Less Non-Cash Adjustments	'	'	836	2,103
Restructuring Accrual Balance	23,349	19,790	23,349	19,790
Severance and other employee costs	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Restructuring Accrual Balance	'	'	22,908	3,089
Restructuring Costs Incurred	3,222	2,606	12,743	22,841
Less Payments	'	'	-12,680	-6,565
Less Non-Cash Adjustments	'	'	0	0
Restructuring Accrual Balance	22,971	19,365	22,971	19,365
Other costs	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Restructuring Accrual Balance	'	'	728	173
Restructuring Costs Incurred	4,249	2,676	9,354	5,317
Less Payments	'	'	-9,704	-5,065
Less Non-Cash Adjustments	'	'	0	0
Restructuring Accrual Balance	378	425	378	425
Accelerated depreciation	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Restructuring Accrual Balance	'	'	0	0
Restructuring Costs Incurred	481	934	740	1,188
Less Payments	'	'	0	'
Less Non-Cash Adjustments	'	'	-740	-1,188
Restructuring Accrual Balance	0	0	0	0
Asset write-down	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Restructuring Accrual Balance	'	'	0	0
Restructuring Costs Incurred	'	'	96	915
Less Payments	'	'	0	0
Less Non-Cash Adjustments	'	'	-96	-915
Restructuring Accrual Balance	$0	$0	$0	$0

RESTRUCTURING_Schedule_of_Rest1

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Transformation costs	$7,393	$12,070	$15,405	$22,128
Restructuring Costs Incurred	7,952	6,802	22,933	30,261
Total restructuring and transformation	15,345	18,872	38,338	52,389
Severance and other employee costs	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Costs Incurred	3,222	2,606	12,743	22,841
Other costs	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Costs Incurred	4,249	2,676	9,354	5,317
Accelerated depreciation	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Costs Incurred	481	934	740	1,188
Asset disposal	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Costs Incurred	0	586	96	915
Transformation and other costs	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Transformation costs	7,225	10,868	14,987	20,083
Accelerated depreciation	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Transformation costs	168	442	418	1,285
Asset disposal	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Transformation costs	$0	$760	$0	$760

CAPITALIZATION_OF_SOFTWARE_DEV1

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Mar. 29, 2014
Research and Development [Abstract]	'	'	'
Capitalized software development costs for ongoing initiatives	$3.50	$2.60	'
Software costs capitalized, net	35.2	'	31.7
Total costs capitalized related to in process software development initiatives	6.7	'	15.6
Capitalized software development costs placed into service	$12.30	'	'

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 1) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance as of March 29, 2014	$1,410
Other comprehensive income (loss) before reclassifications	294
Amounts reclassified from Accumulated Other Comprehensive Income	-1,638
Net current period other comprehensive income	-1,344
Balance as of September 27, 2014	66
Foreign currency	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance as of March 29, 2014	3,198
Other comprehensive income (loss) before reclassifications	-3,446
Amounts reclassified from Accumulated Other Comprehensive Income	0
Net current period other comprehensive income	-3,446
Balance as of September 27, 2014	-248
Defined benefit plans	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance as of March 29, 2014	-4,592
Other comprehensive income (loss) before reclassifications	-597
Amounts reclassified from Accumulated Other Comprehensive Income	0
Net current period other comprehensive income	-597
Balance as of September 27, 2014	-5,189
Net Unrealized Gain/loss on Derivatives	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Balance as of March 29, 2014	2,804
Other comprehensive income (loss) before reclassifications	4,337
Amounts reclassified from Accumulated Other Comprehensive Income	-1,638
Net current period other comprehensive income	2,699
Balance as of September 27, 2014	$5,503

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Sep. 27, 2014	Sep. 28, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Realized net gain on derivatives	($2,645)	($2,542)	($5,188)	($5,183)
Income tax effect	-2,275	-4,340	-1,715	-2,965
Net income	7,487	16,548	3,839	8,674
Net Unrealized Gain/loss on Derivatives | Amounts Reclassified from Other Comprehensive Income	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'	'	'	'
Realized net gain on derivatives	'	'	1,676	'
Income tax effect	'	'	-38	'
Net income	'	'	$1,638	'